Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Số trang: 10
Loại file: pdf
Dung lượng: 1.01 MB
Lượt xem: 7
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs.
Nội dung trích xuất từ tài liệu:
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Nội dung trích xuất từ tài liệu:
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Multiple myeloma Proteasome inhibitor Oral drug Combination therapyGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 166 0 0 -
6 trang 165 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 138 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 107 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 34 0 0
-
12 trang 33 0 0